摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(E)-2-(2-(4-(cyclopropylamino)thieno[3,2-d]pyrimidin-7-yl)vinyl)phenol | 1318127-35-3

中文名称
——
中文别名
——
英文名称
(E)-2-(2-(4-(cyclopropylamino)thieno[3,2-d]pyrimidin-7-yl)vinyl)phenol
英文别名
2-[(E)-2-[4-(cyclopropylamino)thieno[3,2-d]pyrimidin-7-yl]ethenyl]phenol
(E)-2-(2-(4-(cyclopropylamino)thieno[3,2-d]pyrimidin-7-yl)vinyl)phenol化学式
CAS
1318127-35-3
化学式
C17H15N3OS
mdl
——
分子量
309.392
InChiKey
FOGPQQVQRUVDBZ-AATRIKPKSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.1
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    86.3
  • 氢给体数:
    2
  • 氢受体数:
    5

文献信息

  • BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE
    申请人:Jung Seung Hyun
    公开号:US20120302567A1
    公开(公告)日:2012-11-29
    The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    本发明涉及一种新颖的双环杂环芳基衍生物,其药用盐,合物和溶剂合物,具有改进的蛋白激酶抑制活性,并且包括作为活性成分的药物组合物,用于预防或治疗异常细胞生长紊乱。
  • NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING SAME, AND ALKYNYL COMPOUND USED THEREFOR
    申请人:Abe Koji
    公开号:US20120301797A1
    公开(公告)日:2012-11-29
    The present invention provides an excellent nonaqueous electrolytic solution capable of improving low-temperature and high-temperature cycle properties and load characteristics after high-temperature charging storage, an electrochemical element using it, and an alkynyl compound used for it. The nonaqueous electrolytic solution of the present invention comprises containing at least one alkynyl compound represented by the following general formula (I) in an amount of from 0.01 to 10% by mass in the nonaqueous electrolytic solution. R 1 (O) n —X 1 —R 2 (I) (In the formula, X 1 represents a group —C(═O)—, a group —C(═O)—C(═O)—, a group —S(═O) 2 —, a group —P(═O) (—R 3 )—, or a group —X 2 —S(═O) 2 O—. R 1 represents an alkenyl group, a formyl group, an alkyl group, an acyl group, an arylcarbonyl, an alkanesulfonyl group, an alkynyloxysulfonyl group, an arylsulfonyl group, a dialkylphosphoryl group, an alkyl(alkoxy)phosphoryl group, or a dialkoxyphosphoryl group; R 2 represents an alkynyl group or an alkynyloxy group; R 3 represents an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, or an aryloxy group; n indicates 0 or 1.
    本发明提供了一种优秀的非电解质溶液,能够改善低温和高温循环性能以及高温充电存储后的负载特性,以及使用它的电化学元件和用于它的炔基化合物。本发明的非电解质溶液包括以下通式(I)表示的至少一种炔基化合物,其在非电解质溶液中的质量分数为0.01至10%。R1(O)n—X1—R2(I)(在式中,X1表示基团—C(═O)—,基团—C(═O)—C(═O)—,基团—S(═O)2—,基团—P(═O)(—R3)—,或基团—X2—S(═O)2O—。R1表示烯基基团,甲酰基团,烷基基团,酰基团,芳基羰基,烷烷基磺酰基,炔氧基磺酰基,芳基磺酰基,二烷基酰基,烷基(烷氧基)酰基,或二烷氧基酰基;R2表示炔基团或炔氧基团;R3表示烷基,烯基,炔基,芳基,烷氧基,烯氧基,炔氧基,或芳氧基;n表示0或1。
  • Non-aqueous electrolytic solution, electrochemical element using the same and alkynyl compound used therefor
    申请人:Ube Industries, Ltd.
    公开号:EP2883867A2
    公开(公告)日:2015-06-17
    The present invention provides an excellent nonaqueous electrolytic solution capable of improving low-temperature and high-temperature cycle properties and load characteristics after high-temperature charging storage, an electrochemical element using it, and an alkynyl compound used for it. The nonaqueous electrolytic solution of the present invention comprises at least one alkynyl compound represented by the following general formula (I) in an amount of from 0.01 to 10% by mass in the nonaqueous electrolytic solution.          R1(O)n-X1-R2     (I) In the formula, X1 represents a group -C(=O)-, a group -S(=O)2-, or a group -P(=O)(-R3)-. R1 represents an alkenyl group having from 2 to 8 carbon atoms; R2 represents an alkynyl group having from 3 to 8 carbon atoms or an alkynyloxy group having from 3 to 8 carbon atoms; R3 represents an alkyl group, an alkenyl group, an alkynyl group, an aryl group, an alkoxy group, an alkenyloxy group, an alkynyloxy group, or an aryloxy group; n indicates 0 or 1.
    本发明提供了一种能够改善低温和高温循环特性以及高温充电储存后负载特性的优良非基电解溶液、使用该溶液的电化学元件以及用于该溶液的炔基化合物。 本发明的非基电解溶液包含至少一种由下式通式(I)表示的炔基化合物,其在非基电解溶液中的含量为 0.01 至 10%(按质量计)。 R1(O)n-X1-R2 (I) 式中,X1 代表基团-C(=O)-、基团-S(=O)2-或基团-P(=O)(-R3)-。R1 代表具有 2 至 8 个碳原子的烯基;R2 代表具有 3 至 8 个碳原子的炔基或具有 3 至 8 个碳原子的炔氧基;R3 代表烷基、烯基、炔基、芳基、烷氧基、烯氧基、炔氧基或芳氧基;n 表示 0 或 1。
  • Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase
    申请人:Jung Seung Hyun
    公开号:US10112954B2
    公开(公告)日:2018-10-30
    The present invention relates to a novel bicyclic heteroaryl derivative, a pharmaceutically acceptable salt thereof, a hydrate thereof, and a solvate thereof having an improved inhibitory activity for protein kinases, and a pharmaceutical composition for preventing or treating an abnormal cell growth disorder comprising same as an active ingredient.
    本发明涉及一种新型双环杂芳基衍生物、其药学上可接受的盐、其合物和其溶液,该衍生物对蛋白激酶的抑制活性有所提高,本发明还涉及一种用于预防或治疗异常细胞生长紊乱的药物组合物,该药物组合物的有效成分包括双环杂芳基衍生物、其药学上可接受的盐、其合物和其溶液。
  • NON-AQUEOUS ELECTROLYTIC SOLUTION, ELECTROCHEMICAL ELEMENT USING THE SAME, AND ALKYNYL COMPOUND USED THEREFOR
    申请人:Ube Industries, Ltd.
    公开号:EP2533344B1
    公开(公告)日:2016-07-20
查看更多

同类化合物

林扎戈利 替普司特 噻吩并[3,4-d]嘧啶-2,4(1H,3H,5H,7H)-二酮 噻吩并[3,2-d]嘧啶-7-甲胺 噻吩并[3,2-d]嘧啶-4-腈 噻吩并[3,2-d]嘧啶-4-羧酸 噻吩并[3,2-d]嘧啶-4(1H)-硫酮 噻吩并[3,2-d]嘧啶,4-(甲硫基)- 噻吩并[3,2-d]嘧啶 噻吩并[3,2-D]嘧啶-7-羧酸 噻吩并[3,2-D]嘧啶-7-甲醛 噻吩并[3,2-D]嘧啶-7-基甲醇 噻吩并[3,2-D]嘧啶-2-胺 噻吩并[2,3-d]嘧啶-4-胺 噻吩并[2,3-d]嘧啶-4-硫醇 噻吩并[2,3-d]嘧啶-4(3H)-酮 噻吩并[2,3-d]嘧啶-2-乙酸,1,4-二氢-4-羰基-5-苯基-,甲基酯 噻吩并[2,3-d]嘧啶-2,4-二胺 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(4-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,5-(溴甲基)-3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-甲氧苯基)-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(3-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮,3-(2-氯苯基)-1-[(2,6-二氟苯基)甲基]-6-(4-甲氧苯基)-5-甲基- 噻吩并[2,3-d]嘧啶 噻吩并[2,3-D]嘧啶-6-羧酸 噻吩并[2,3-D]嘧啶-6-甲醛 吡啶并[3’,2’:4,5]噻吩并[3,2-d]嘧啶-4(3h)-酮 乙酸,[[5-(4,5-二甲基-2-苯基噻吩并[2,3-d]嘧啶-6-基)-1,3,4-噁二唑-2-基]硫代]-,乙基酯 乙基3-甲基-5-羰基-5H-[1]苯并噻吩并[2,3-d][1,3]噻唑并[3,2-a]嘧啶-2-羧酸酯 乙基2-(4-氯苯基)-7-甲基-9-羰基-9H-[1,3]噻唑并[3,2-a]噻吩并[3,2-d]嘧啶-6-羧酸酯 {[((4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)甲基]硫基}乙酸 [(6-甲基噻吩并[2,3-d]嘧啶-4-基)硫基]乙酸 [(4-氧代-3,4,5,6,7,8-六氢[1]苯并噻吩并[2,3-d]嘧啶-2-基)硫基]乙酸 PI3K抑制剂 PF-3758309抑制剂 Necrostatin-5; 2-[[3,4,5,6,7,8-六氢-3-(4-甲氧基苯基)-4-氧代[1]苯并噻吩并[2,3-d]嘧啶-2-基]硫代]-乙腈 N-甲基-1-噻吩并[3,2-d]嘧啶-4-基-4-哌啶甲胺 N-[2-[[3,4-二氢-4-氧代-3-[4-(2,2,2-三氟乙氧基)苯基]噻吩并[3,4-d]嘧啶-2-基]硫基]乙基]乙酰胺 N-[(1S)-2-(二甲基氨基)-1-苯基乙基]-2,6-二氢-6,6-二甲基-3-[(2-甲基噻吩并[3,2-d]嘧啶-4-基)氨基]-吡咯并[3,4-c]吡唑-5(4H)-甲酰胺盐酸盐 N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-3-(2-甲氧基苯基)-4-氧噻吩并[3,2-d]嘧啶-2-基)硫代]-乙酰胺 N-(4-氟苯基)-5,6-二甲基噻吩并[2,3-D]嘧啶-4-胺 N-(4-吗啉-4-基噻吩并[2,3-e]嘧啶-2-基)乙烷-1,2-二胺 N,N-二甲基-5,6,7,8-四氢苯并[4,5]噻吩并[2,3-D]嘧啶-4-胺 IWP2;N-(6-甲基-2-苯并噻唑基)-2-[(3,4,6,7-四氢-4-氧代-3-苯基噻吩并[3,2d]嘧啶-2-基)硫基]乙酰胺 AR-C 155858; (S)-6-[(3,5-二甲基-1H-吡唑-4-基)甲基]-5-[(4-羟基异噁唑烷-2-基)羰基]-1-异丁基-3-甲基噻吩并[2,3-d]嘧啶-2,4(1H,3H)-二酮 7-甲基噻吩并[3,2-D]嘧啶-4-胺 7-甲基-噻吩并[3,2-d]嘧啶-2,4(1h,3h)-二酮 7-甲基-噻吩并[3,2-d]嘧啶 7-甲基-5,6,7,8-四氢[1]苯并噻吩并[2,3-d]嘧啶-4(3h)-酮 7-甲基-5,6,7,8-四氢-苯并[4,5]噻吩并[2,3-d]嘧啶-4-硫醇